Latest Research Highlights

• INN (International Nonproprietary Name): Mometasone furoate
• Brand Names Available In Canada (English): Elocon and generic mometasone products (check DIN and provincial listings)
• ATC Code: D07AC13
• Forms & Dosages: Cream 0.1% (15g, 30g), Ointment 0.1% (15g, 30g), Lotion 0.1% (30mL)
• Manufacturers In Canada (English): Organon (reference brand Elocon) and multiple generic suppliers (e.g., Glenmark, Teva, Sandoz) — availability varies by pharmacy
• Registration Status In Canada (English): Not specified
• OTC / Rx Classification: Prescription Only (Rx) in most jurisdictions

Recent summaries from 2022–2025 continue to support mometasone furoate as an effective, potent topical corticosteroid for short courses in eczematous and inflammatory dermatoses.

Comparative reviews show efficacy similar to other potent group‑III topical steroids and generally favourable local tolerability when used according to guidance.

Canadian reviews emphasise limiting duration and treated area to reduce systemic absorption, particularly in children and on thin skin.

Placebo‑controlled trials and real‑world registries report rapid symptom reduction for flares, often within days to two weeks, while safety signals link prolonged or occluded use to atrophy and possible HPA axis effects.

Data Highlights

Time‑to‑Improvement: Many patients notice relief within 3–7 days; typical acute response within 1–2 weeks.

Incidence Of Local Adverse Effects: Not specified in supplied data.

• Implication: Use once‑daily mometasone furoate for short courses to control flares and reduce risk of skin atrophy.
• Implication: Avoid occlusion and treat limited surface areas, with extra caution in children and on thin skin (face, intertrigo).
• Implication: Provide bilingual counselling and clear stop dates to meet Canadian patient expectations and support follow‑up.

Basic Elocom Information

• INN (International Nonproprietary Name): Mometasone furoate
• Brand names available in Canada (English): Elocon and various generics (Organon reference product and generic manufacturers such as Glenmark, Teva, Sandoz; check DIN on label)
• ATC Code: D07AC13 (Corticosteroids, potent, group III, for topical use)
• Forms & dosages: Cream 0.1% (15g, 30g tubes); Ointment 0.1% (15g, 30g tubes); Lotion 0.1% (30mL bottles); lotions/solutions preferred for scalp use
• Manufacturers in Canada (English): Organon (reference) and multiple generics; specific Canadian market manufacturers not specified
• Registration status in Canada (English): Not specified
• OTC / Rx classification: Prescription Only (Rx) in most jurisdictions

Clinical Effectiveness In Canada

Clinicians in Canada refer to product monographs and provincial formularies when selecting mometasone furoate for patients.

The INN is Mometasone furoate and the ATC classification is D07AC13, indicating a potent topical corticosteroid class.

Once‑daily application of a thin layer to affected areas is the standard adult regimen and produces clinical improvement in atopic dermatitis, limited plaque psoriasis, seborrheic dermatitis and lichen planus.

Practical prescribing requires verification of Health Canada Drug Product Database entries and local DINs for current marketed brands.

Provincial coverage varies and some formularies list mometasone products under special authorisation rules.

Effectiveness

Rapid anti‑inflammatory effect with visible improvement in days to 2 weeks.

Limitations

Generally avoid use on the face and intertriginous areas unless a specialist directs it, due to thinner skin and higher absorption risk.

• Monitoring: watch for skin atrophy at application sites.
• Monitoring: in children monitor growth and consider HPA axis checks if large surface area treated.
• Monitoring: document DIN and advise follow‑up for chronic or repeat courses.

Indications And Expanded Uses

Approved and commonly used indications include atopic dermatitis, eczema, seborrheic dermatitis, lichen planus and limited plaque psoriasis.

Product summaries list these indications while noting exceptions for face, groin and axilla unless specifically prescribed by a specialist.

Off‑label uses in specialist dermatology settings may include other steroid‑responsive dermatoses under supervision.

• Clinical tip: For Indigenous, rural or remote communities, provide explicit stop dates and arrange local pharmacist or nurse follow‑up when access to dermatology is limited.
• Site‑Specific Cautions: avoid face, groin and axilla in most patients; in infants and children follow paediatric cautions closely.

Composition And Brand Landscape

The International Nonproprietary Name is Mometasone furoate and the original brand is Elocon, manufactured by Organon.

Major global manufacturers include Organon and multiple generics from Glenmark, Teva, Sandoz and others.

Common forms and package sizes recorded are cream 0.1% in 15g and 30g tubes, ointment 0.1% in 15g and 30g tubes, and lotion 0.1% in 30mL bottles.

• Cream Versus Ointment Versus Lotion: creams are cosmetically acceptable and common for eczematous disease.
• Ointments offer greater occlusion and moisturisation but are greasier and may be preferred in dry winter months in Canada.
• Lotion and solution forms are useful for scalp disease and hair‑bearing areas.

Retail chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs commonly stock both brand and generic options, though rural pharmacies may carry limited formulations.

Contraindications And Special Precautions

Mometasone furoate is contraindicated in patients with known hypersensitivity to the active substance or excipients.

Local untreated infections — bacterial, viral, fungal or parasitic — are absolute contraindications until the infection is controlled.

Rosacea, acne vulgaris and perioral dermatitis are listed as conditions where topical potent corticosteroids should not be used.

Absolute Contraindications

Hypersensitivity to mometasone furoate or excipients; untreated cutaneous infections; rosacea, acne vulgaris, perioral dermatitis.

Relative Contraindications

Children (systemic absorption/atrophy risk), extensive broken skin, prolonged use or occlusion, elderly with fragile skin, pregnancy and lactation (use only if clearly needed).

• Red Flags For Immediate Review: sudden rapid spread of rash, signs of secondary infection (pus, fever), or systemic symptoms.
• Prescribing Note: in Indigenous and long‑term care populations, baseline skin fragility may be higher — start conservatively and arrange nursing or pharmacist review.

Dosage Guidelines

Standard adult dosing is to apply a thin layer once daily to affected areas.

For scalp conditions, use the lotion or solution once daily as directed.

Children should receive short courses only and mometasone is not recommended in children under 2 years of age.

When treating children older than 2 years, limit courses to less than three weeks where possible and avoid occlusion.

• Face: generally avoid unless specialist‑directed.
• Trunk and Limbs: thin layer once daily.
• Scalp: lotion/solution once daily.

Typical treatment durations are acute 1–2 weeks, with longer use requiring medical supervision and tapering strategies.

Check provincial drug plan quantity limits before dispensing; pharmacists often provide printed fingertip unit charts as patient handouts.

Interactions Overview

Topical mometasone furoate has minimal systemic drug‑drug interactions when used as directed for limited areas.

Systemic corticosteroid interactions become clinically relevant only when significant systemic absorption occurs, such as with large body surface area treatment, prolonged use or occlusion.

Strong CYP3A4 inhibitors can increase systemic corticosteroid effects with systemic corticosteroids, but significant interaction from topical mometasone is unlikely unless systemic absorption is present.

• Interaction Risk Scenarios: extensive application, broken skin, paediatric use, occlusion, or concurrent use of multiple potent topical steroids.
• Topical OTC Considerations: tell patients to disclose all creams and OTC products, as some can mask infections or increase irritation.
• Medication Review: check for systemic steroid exposure in patients on chronic oral corticosteroids and consult the pharmacist for a full medication review.

Cultural Perceptions And Patient Habits

Many Canadian patients express caution about topical steroids, commonly referred to as “steroid phobia.”

Online provincial groups and forums often contain questions about long‑term safety, cosmetic effects and use in children.

Rural patients may delay care due to travel or limited clinics and therefore rely heavily on community pharmacists for triage and counselling.

Bilingual patient information (English/French) and clear plain‑language stop/start instructions improve adherence and reduce misuse.

• Common Patient Concerns: skin thinning, rebound flare after stopping, and systemic absorption — address these with clear duration and monitoring plans.
• Indigenous Communities: favour culturally safe communication and involve community health nurses or telederm options when available.

Top Patient Priorities: safety, clear duration, and alternative options.

Availability And Pricing Patterns

Elocon and multiple generics such as Glenmark, Teva and Sandoz are listed in global supply data in cream, ointment and lotion 0.1% formulations.

In Canada, mometasone products are typically prescription‑only and availability varies by pharmacy chain and region.

Pricing and coverage depend on provincial plans such as ODB, BC PharmaCare and RAMQ; some plans list mometasone under standard or special authorisation rules.

Tip For Patients: ask for a generic mometasone product if cost is a concern and request quantity aligned with the expected short treatment duration.

In our online pharmacy, elocom is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Comparable Medicines And Preferences

Potency‑class competitors include betamethasone, fluticasone and triamcinolone, with clobetasol classified as superpotent and not a direct equivalent.

• Pros Of Mometasone: once‑daily dosing and a range of cosmetic formulations including lotions for scalp use.
• Cons Of Mometasone: potent steroid risk if misused; requires clear duration and area limits.
• Formulary Tip: clinicians should check DIN‑based alternatives when seeking covered options for patients.

Frequently Asked Questions

• Is Elocon Safe For Children? Short courses are used in children over 2 years with caution; it is not recommended for children under 2 years and occlusion should be avoided.
• Can I Buy Elocon Without A Prescription In Canada? Mometasone products are prescription‑only in most jurisdictions; consult a prescriber or use local pharmacy services for assessment.
• How Long Until I See Improvement? Many patients notice symptom relief within 3–7 days; a typical acute course is 1–2 weeks.
• What About Steroid Withdrawal Or Rebound? Rebound can occur with overuse; follow prescribed durations and taper per clinician instructions.
• Can I Use Elocon On My Face? Generally avoid facial use unless directed by a specialist because facial skin is thinner and more prone to atrophy.

Patient Action: if using for more than two weeks, book a follow‑up appointment and check with your pharmacist if you are also on systemic steroids.

Guidelines For Proper Use

Counselling should focus on applying a thin layer once daily, adhering to a clear stop date and avoiding occlusion unless specifically instructed.

For children, follow paediatric cautions and keep courses as short as possible, generally under three weeks when feasible.

• Dispensing Checklist: confirm indication, review other topical and systemic medications, provide fingertip unit guidance and printed instructions.
• Red Flags To Advise Patients: worsening rash, signs of infection, new pustules, systemic symptoms or unexpected skin thinning.

Patient Handout Elements: bilingual (English/French) instructions, a fingertip unit table, storage guidance (store at 25°C; excursions 15–30°C; protect from freezing) and a clear stop date.

Document the DIN on the pharmacy record and encourage reporting adverse effects to Health Canada via MedEffect if patients experience significant reactions.

Delivery Across Canada (English)